Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Durvalumab in Metastatic Pancreatic Cancer with DDR Alterations
NCT05659914Phase 2Active, not recruiting
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Started Nov 2022; status: active, not recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05659914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659914.